1Pizza M,Giuliani MM,Fontana MR,et al.Mucosal vaccines:non-toxin derivatives of LT and CT as mucosal adjuvants.Vaccine,2001,19:2534-2541.
2Magagnoli C,Manetti R,Fontana MR,et al.Mutations in the A subunit affect yield,and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin.Infect Immun,1996,64:5434-5438.
3Giudice GD,Podda A,Rappuoli R.What are the limits of adjuvanticity?Vaccine,2002,20:S38-S41.
5De Haan L,Holtrop M,Verweij WR,et al.Mucesal immunogenicity of the Escherchia coli heat-labile enterotoxin:role of the A subunit.Vaccine,1996,14:260-266.
6Lewis SM,Osei-Bimpong A.Haemoglobinometry in general practice.Clin L8ab Haematol,2003,25:343-346.
7De Haan L,Verweij WR,Agsteribbe E,et al.Mucosal immunogenicity and adjuvant activiy of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin.Immunol,1999,97:706-713.
8De Haan L,Verweij WR,Holtrop M,et al.Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Esherichia coli heat-labile toxin induce IgA-or IgG-mediated protective mucosal immunity.Vaccine,2001,19:2898-2907.
9Kotloff KL,Sztein MB,Wasserman SS,et al.Safety and immunogenicity of oral inactivated whole-cell Hdicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.Infect Immun,2001,69:3581-3590.
10Cheng E,Freytag LC,Clemants JD.The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT).Vaccine,2000,18:38-49.
